awmsg logo



ethinylestradiol/drospirenone (Flexyess®)


Reference No. 2021

Publication date:
01/08/2013


Appraisal information

ethinylestradiol/drospirenone (Flexyess®) 0.02 mg/3 mg film-coated tablet


Company: Bayer Healthcare Pharmaceuticals
BNF category: Obstetrics, gynaecology, and urinary-tract disorders
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ethinylestradiol/drospirenone (Flexyess®) cannot be endorsed for use within NHS Wales as oral contraception.
Statement of Advice (SOA)
Download